Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    facet.materialart.
    Unknown
    Zur Handlungsstruktur von Comics und Märchen (1978)
    Berlin : Periodicals Archive Online (PAO)
    Fabula. 19:3/4 (1978) 262 
    Details
    ISSN: 0014-6242
    Topics: Linguistics and Literary Studies
    URL: http://gateway.proquest.com/openurl?url_ver=Z39.88-2004&res_dat=xri:pao:&rft_dat=xri:pao:article:4094-1978-019-03-000006
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders (1987)
    Springer
    Cancer immunology immunotherapy 25 (1987), S. 266-273 
    Details
    ISSN: 1432-0851
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary During previous therapeutic trials with interferon, decreased levels of peripheral platelet counts have been observed. Taking advantage of this effect, we investigated the efficacy of recombinant interferon (rec-IFN) in the treatment of thrombocytosis in myeloproliferative diseases. A total of 15 patients with polycythemia vera, essential thrombocytosis, or chronic myeloid leukemia received rec-IFN-alfa at initial doses of 25–70×106 units/week; maintenance therapy following week 8 of treatment consisted of 20–35×106 units/week rec-IFN. Observation periods ranged from 24 to 48 weeks. Significant reductions in the number of platelets were noted in all cases; 12/15 patients achieved platelet counts below 440×109/1 and maintained those normal values for at least 4 weeks. The number of bone marrow megakaryocytes, which had been increased prior to treatment, diminished during rec-IFN therapy, while the previously shortened platelet half-life further decreased with rec-IFN treatment. During rec-IFN-induced remission, the plasma levels of platelet factors, the activity of natural killer cells, and platelet aggregation showed changes between slight improvement and normal values. Severe side effects were only observed with the highest rec-IFN doses; dosage adjustments were effective in improving or eliminating all treatment-related symptoms. Rec-IFN may prove to be a valuable therapeutic alternative to cytostatic treatment of thrombocytosis in myeloproliferative disorders.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00199157
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    In vitro inhibitory effect of interferon on colony formation of myeloma stem cells (1980)
    Springer
    Cancer immunology immunotherapy 9 (1980), S. 139-143 
    Details
    ISSN: 1432-0851
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The inhibitory effect of interferon on colony formation of myeloma stem cells in two layer plasma clot-soft agar cultures was studied. Human lymphoblast interferon inhibited in therapeutically attainable concentrations myeloma stem cell proliferation in 50% and human fibroblast interferon in 23% of the 14 myeloma patients in whom in vitro colony formation could be achieved. In interferon-sensitive patients the numbers of myeloma stem cell clusters and colonies were decreased to 34.4%–54.9% of control cultures. In addition, maturation of myeloma stem cells in differentiated plasma cells was reduced by interferon in most of these cases.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00205617
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Maximal androgen blockade in combination with methotrexate for treatment of metastatic prostate cancer (1996)
    Springer
    Journal of cancer research and clinical oncology 122 (1996), S. 171-176 
    Details
    ISSN: 1432-1335
    Keywords: Prostate cancer ; Maximal androgen blockade ; Methotrexate ; Randomized trial
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Recently attention has been focused on the optimal timing of chemotherapy within the treatment regimen for patients with metastatic prostate cancer, i.e., hormonal manipulation, preferably maximal androgen blockage (MAB) consisting of chemical/surgical castration followed by treatment with antiandrogens. We have conducted a randomized prospective clinical trial, investigating the efficacy and toxicity of MAB (orchiectomy followed by flutamide therapy) alone as compared to MAB combined with methotrexate (MTX, 50 mg/m2/week) in 53 patients with newly diagnosed stage IV (M1) prostatic cancer (UICC TNM Classification 1987). The observed remission rates (complete+partial) of 42.3% in the MAB+MTX arm and 29.6% in the MAB arm did not differ significantly. The response rates (complete+partial+stable disease) of 73.1% and 66.7% for MAB+MTX and MAB, respectively, also showed no significant difference. Neither progression-free survival (median: 18.5 and 23.8 months for MAB+MTX and MAB, respectively) nor overall survival (median: 37.4 and 36.1) months in the MAB+MTX and MAB arm, respectively) could be improved by the addition of MTX to MAB. Only the extent of metastatic pain reported by the patients was consistently less under MAB+MTX than under MAB alone (P〈0.1). Both treatment regimens were well-tolerated with slightly more undesirable effects in the MAB+MTX arm. Our results do not provide evidence for the achievement of marked gains by combining chemotherapy with endocrine therapy in newly diagnosed patients with stage IV (M1) prostate cancer.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01366958
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment (1985)
    Springer
    Breast cancer research and treatment 6 (1985), S. 89-93 
    Details
    ISSN: 1573-7217
    Keywords: adriamycin ; advanced breast cancer ; cardiotoxicity ; doxorubicin ; second-line treatment
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Weekly low dose doxorubicin monotherapy was evaluated in heavily pretreated patients with metastatic breast cancer. 19 patients received 8–12 mg/m2 doxorubicin/week for a treatment period of up to 7 months until a progression of the disease occurred (mean number of weekly courses 15 ± 8). In 2 of 17 evaluable patients, an objective response with a duration of 3+ and 5 months respectively was achieved. In 9 patients a stabilisation of the disease was observed (mean duration of DS 4 mos ±2), whereas the disease progressed in 6. The tolerance for this regimen was remarkable, with neither serious acute toxocity nor any signs of congestive cardiomyopathy even in those patients who were treated beyond a cumulative dose of 450 mg/m2. Weekly low dose doxorubicin monotherapy shows modest activity, but is devoid of severe toxicity in heavily pretreated patients with metastatic breast cancer. An increase in the therapeutic index was not observed.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01806014
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Pirarubicin (4′-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer (1990)
    Springer
    Investigational new drugs 8 (1990), S. 207-210 
    Details
    ISSN: 1573-0646
    Keywords: pirarubicin ; anthracycline ; breast cancer ; phase II trial
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary In a phase II study, 77 patients with metastatic breast cancer were treated with pirarubicin, 70 mg/m2 iv every 3 weeks. Most of them had received prior hormonal (n = 39) and/or chemotherapeutic drug treatment for advanced disease, including anthracycline-containing regimens in 17. After a median of 5.5 treatment cycles (range 1–14), objective tumor response was seen in 22/71 (31%) evaluable patients (4CR, 18 PR). Stable disease occurred in 34 (48%) patients, whereas the tumor progressed in 15 (21%). Significant hematologic toxicity (WHO grade III–IV) requiring interval and/or dose adjustments was observed in 41 (58%) patients. Other treatment-related side effects were generally mild, and included alopecia in 52 (73%), nausea and/or emesis in 50 (70%), and stomatitis and diarrhea in 3 patients each. There was no treatment-related death, nor was there any evidence of cardiac toxicity thus far. In summary, the early results of this trial suggest that pirarubicin is an active and rather well tolerated drug in pretreated patients with advanced breast cancer.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00177262
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report (1985)
    Springer
    Investigational new drugs 3 (1985), S. 315-318 
    Details
    ISSN: 1573-0646
    Keywords: vincristine ; side effects ; CNS-toxicity
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Neurotoxicity is a well-recognized and commonly observed side effect associated with the use of vincristine sulfate in cancer chemotherapy. The clinical manifestations of vincristine neuropathy cover a wide spectrum of peripheral neurologic dysfunctions that have been described to be reversible and cumulative in most instances (1, 2). Paresthesias, loss of tendon reflexes, and progressive weakness are the most common clinical features (3, 4). Sensory impairment, cranial nerve palsies, gastrointestinal disturbances, and autonomie dysfunctions including atonic bladder, impotence, and orthostatic hypotension may occur (5). Acute CNS complications, usually presenting as generalized seizures, are extremely rare and only a few cases have been reported which were without underlying biochemical or structural abnormalities (1, 5–9). We describe the case of a woman with multiple myeloma, who developed fulminant encephalopathy following 4 days of continuous vincristine, adriamycin, and day 1–4 pulse dexamethasone (VAD) combination therapy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00179439
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    Zur Bildung von Benzo-isoindolen (1954)
    Weinheim : Wiley-Blackwell
    Liebigs Annalen 589 (1954), S. 55-76 
    Details
    ISSN: 0075-4617
    Keywords: Chemistry ; Organic Chemistry
    Source: Wiley InterScience Backfile Collection 1832-2000
    Topics: Chemistry and Pharmacology
    Additional Material: 4 Ill.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1002/jlac.19545890107
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 9
    Electronic Resource
    Electronic Resource
    Farbige Kohlenwasserstoffe der Diphensuccindenreihe. Über einen unregelmäßigen Verlauf der Grignardschen Reaktion. XI. Mitteilung über Verbindungen der Diphensuccindenreihe (1925)
    New York, NY : Wiley-Blackwell
    Journal für Praktische Chemie/Chemiker-Zeitung 110 (1925), S. 26-36 
    Details
    ISSN: 0021-8383
    Keywords: Chemistry ; Organic Chemistry
    Source: Wiley InterScience Backfile Collection 1832-2000
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1002/prac.19251100103
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...